Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Monday, 24 July 2017

CLINUVEL Newsletter – July 2017

10 July 2017   For those who have followed the Company over the years, the journey of our teams has most often been countercurrent to arrive at the present point. Rather than traversing along the fastest imaginable and plotted route to success, we have frequently been impelled to take tortuous avenues to achieve our objectives. […]

Download PDF
 
 
Wednesday, 10 May 2017

Appendix 3B

10 May 2017   enclosed is a new issue announcement, application for quotation of additional securities and agreement.   Download PDF for more

Download PDF
 
 
Wednesday, 10 May 2017

CLINUVEL Newsletter – May 2017

10 May 2017   I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end. Key observations from this procedure are that insurers are coordinating efforts internationally to cull healthcare costs, and will come up with any conceivable […]

Download PDF
 
 
Monday, 01 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

2 May 2017   CLINUVEL PHARMACEUTICALS LIMITED today announced that the Department of Health (DoH) has designated SCENESSE® (afamelanotide 16mg) to be evaluated as a Highly Specialised Technology (HST). The re-classification acknowledges that the National Institute for Health and Care Excellence (NICE) committed an error in its earlier assessment of SCENESSE® as only eligible for […]

Download PDF
 
 
Thursday, 27 April 2017

Appendix 4C – Quarterly report

28 April 2017   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders announced today its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2017.   Download […]

Download PDF
 
 

  12 April 2017   CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited: Class Number                    Exercise price     […]

Download PDF
 
 

12 April 2017   CLINUVEL today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the treatment of erythropoietic protoporphyria (EPP) patients with CLINUVEL’s drug SCENESSE®    CLINUVEL had been in mandatory ‘negotiation’ with GKV-SV since August 2016. Under the German Pharmaceuticals Market Reorganisation […]

Download PDF
 
 
Friday, 24 February 2017

Appendix 4D and Half Year Report

24 February 2017   Your Directors present their report on the Company and its controlled entities for the half year ended 31 December 2016. The result from ordinary activities attributable to CLINUVEL PHARMACEUTICALS LIMITED for the half year was a net profit of $2,522,519, representing a 177% improvement to the financial result for the same […]

Download PDF
 
 
Wednesday, 15 February 2017

CLINUVEL Newsletter – February 2017

16 February 2017   I wish all stakeholders of the CLINUVEL Group a healthy, mindful and successful 2017. After a Christmas break CLINUVEL started 2017 with fervour and ‘en bon esprit’. We look forward to an exciting year. During a meeting on 4 February in London international expert physicians, senior and paediatric patients, family carers […]

Download PDF
 
 
Tuesday, 31 January 2017

Appendix 4C – Quarterly report

31 January 2017   Enclosed is the quarterly report for the period ending 31 December 2016.   Download PDF for more

Download PDF
 
 
Thursday, 22 December 2016

Appendix 3Y

22 December 2016   We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.   Download PDF for more

Download PDF
 
 
Tuesday, 20 December 2016

CLINUVEL Newsletter – December 2016

20 December 2016   At the end of a calendar year we look back on plenty of activities and a solid financial performance by the CLINUVEL Group. Our teams will break over the season’s holidays to reflect on a hectic year, but most of all to prepare ourselves physically and mentally for more exciting challenges […]

Download PDF
 
 
Monday, 12 December 2016

Appendix 3Y

12 December 2016   We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.   Download PDF for more

Download PDF
 
 
Monday, 28 November 2016

Results of Meeting

28 November 2016 In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. Download PDF for more

Download PDF
 
 

27 November 2017   I would like to commence my address by saying it is always a pleasure to welcome familiar and a few new faces to the CLINUVEL Annual General Meeting. It has indeed been quite a journey since the early 2000’s, working in an environment of constant change requiring repeated changes of direction […]

Download PDF
 
Thursday, 05 December 2019

Appendix 3B

 New issue announcement, application for quotation of additional securities and agreement. 

Download PDF
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day …

Download PDF
 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[...]

Download PDF
 

 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF